Lasmiditan, a drug approved for treatment of migraine, was placed in Schedule V of the Controlled Substances Act effective Jan. 31 (85 Fed. Reg. 5557). Known by the trade name Reyvow, lasmiditan was approved by the U.S. Food and Drug Administration in October 2019 for the treatment of acute migraine in adults, with or without aura. In its notification of approval to the Drug Enfor... Read More